Navigation Links
Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy

tients treated so far with QbG10 in the different studies, we can see the following
picture: QbG10 seems to be active as a monotherapy; however, combination with an allergen extract
at a standard dose appears to enhance the therapeutic effect. The highest efficacy was achieved
when QbG10 was combined with a dose of allergen extract usually applied in conventional
desensitization therapy, i.e. a 10-times higher dose than the one tested in this present study. In a
next clinical trial we will test higher doses of CYT003-QbG10 monotherapy and compare the safety
and efficacy profile directly with the most promising product formulations of CYT005-AllQbG10 in
order to select the best product candidate for late stage development.”

CYT003-QbG10 Conference Call and Webcast
Cytos Biotechnology will host a conference call and Q&A session today, Tuesday, May 15, 2007 at
10 am (CET) to discuss the study findings.
To access the conference call, please dial the following numbers:
Europe +41 91 610 56 00
U.S. +1 866 291 41 66
U.K. +44 207 107 06 11

The conference call will be held in English and will also be accessible by webcast on the internet.
You may follow the call live or have it replayed later on demand. To access the webcast and the
presentation, please follow the link provided on our homepage www.cytos.com. The presentation
slides will be available for download 30 minutes prior to the conference call.

Among other projects, Cytos Biotechnology will also discuss its allergy program at the company’s
upcoming R&D day on Wednesday, June 20, 2007 at 2 pm (CET) at the company’s premises in
Schlieren.

About the phase IIa study and the analysis
The multi-centre, randomized, double-blind and placebo-controlled phase IIa study included 40 male'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. ... the United States , European Union ... EMA and MHLW, respectively) for eribulin, for the treatment ... have received prior chemotherapy for advanced or metastatic disease. ... data from a pivotal global Phase 3 clinical trial ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Oncobiologics announced today that it has signed two ... early-stage biotech company, and involves worldwide licensing for an ... based large pharmaceutical company to conduct research focused on ... The identity of the client firm was not disclosed ...
... Oct. 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. ... China-based advanced in-vitro diagnostic ("IVD") company, today announced that ... approved the Company,s real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma ... as a companion diagnostic test for the use of ...
Cached Medicine Technology:Oncobiologics, Inc. Announces Two New Agreements Worth Close to $80 Million 2China Medical Technologies Receives SFDA Approval for its PCR-based KRAS Assay for Colorectal Cancer Targeted Drug 2
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable ... on in Chicago at Grant Park. The festival will end on Sunday, August ... to Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, the Mesothelioma Applied ... can be accessed by visiting http://www.curemeso.org/store . , “Our new store features ... part: whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to ... it comes time to cook the next meal, making July the most appropriate to ... best grilling tips and recipes. , Make the next cookout different than the ones ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Coco Libre ... athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, July ... water that can claim “no added sugar” on the market, is a natural choice ...
(Date:7/31/2015)... ... ... According to the article published July 27 on My News LA, a fire ... by the city’s fire department before it caused major damage throughout the building. The article ... and it was a fire alarm system that tipped off fire fighters so they could ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... rise in Britain last year with ethnic South Asians//, ... ,According to figures released by Britain's Health Protection ... TB cases in Britain, with 8,113 cases in 2005 ... of cases, 38 percent, was reported among people from ...
... of twenty four new drugs to combat HIV infection ... are plenty.// But the crux of the issue is the ... life expectancy by almost 24 years comes tagged with a ... a Cornell/Johns Hopkins/Harvard/Boston University research team analyzed the costs ...
... on mercury based flu vaccines given to pregnant women// and ... . This decision was made due to a vaccine shortage ... vaccine is manufactured by Sanofi pasteur, and the governor Arnold ... production to meet the state's need. ,The waiver was ...
... kits well past the expiry date , used to screen ... infections was found during raids conducted at Calcutta from ... company Monozyme India which had several contracts with the state ... forcibly calling back kits that have been already dispatched by ...
... of dengue, later confirmed positive for the fever, taking the ... ,Nearly 31 deaths have been confirmed with the ... of Health (NIH) has reiterated via a press release that ... in from all over Pakistan which is being tested quickly ...
... with low level of folic acid increases the risk of ... Research. ,This investigation carried out by scientists at ... disease and also how to prevent it. This research was ... which, they had shown how folate-rich diets offer protection against ...
Cached Medicine News:Health News:Low Folate Diet increases Colorectal Cancer risk 2
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
... Tm Bioscience introduces the Tag-It™ Cystic ... for cystic fibrosis genotyping. With validated performance ... assay will provide superior mutation coverage for ... aid to diagnosis in newborns. ,The ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: